Aims Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular
death among patients with heart failure with mildly reduced or preserved ejection fraction. In …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Background Patients with heart failure (HF) have a high burden of multimorbidity, often
necessitating numerous medications. There may be clinical concern about introducing …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Importance Sodium-glucose cotransporter 2 inhibitors are known to reduce heart failure
events and slow progression of kidney disease among patients with heart failure and a …

Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved
Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Aims This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of
dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF)> 40% varied by …